146 related articles for article (PubMed ID: 19513504)
1. AFPep, a novel drug for the prevention and treatment of breast cancer, does not disrupt the estrous cycle or fertility in rats.
Tower AM; Trinward A; Lee K; Joseph L; Jacobson HI; Bennett JA; Andersen TT
Oncol Rep; 2009 Jul; 22(1):49-56. PubMed ID: 19513504
[TBL] [Abstract][Full Text] [Related]
2. Prevention of N-methyl-N-nitrosourea-induced breast cancer by alpha-fetoprotein (AFP)-derived peptide, a peptide derived from the active site of AFP.
Parikh RR; Gildener-Leapman N; Narendran A; Lin HY; Lemanski N; Bennett JA; Jacobson HI; Andersen TT
Clin Cancer Res; 2005 Dec; 11(23):8512-20. PubMed ID: 16322315
[TBL] [Abstract][Full Text] [Related]
3. AFPep: an anti-breast cancer peptide that is orally active.
Bennett JA; DeFreest L; Anaka I; Saadati H; Balulad S; Jacobson HI; Andersen TT
Breast Cancer Res Treat; 2006 Jul; 98(2):133-41. PubMed ID: 16538538
[TBL] [Abstract][Full Text] [Related]
4. An alpha-fetoprotein-derived peptide reduces the uterine hyperplasia and increases the antitumour effect of tamoxifen.
Andersen TT; Georgekutty J; Defreest LA; Amaratunga G; Narendran A; Lemanski N; Jacobson HI; Bennett JA
Br J Cancer; 2007 Aug; 97(3):327-33. PubMed ID: 17637684
[TBL] [Abstract][Full Text] [Related]
5. Antiestrogenic and anticancer activities of peptides derived from the active site of alpha-fetoprotein.
Joseph LC; Bennett JA; Kirschner KN; Shields GC; Hughes J; Lostritto N; Jacobson HI; Andersen TT
J Pept Sci; 2009 Apr; 15(4):319-25. PubMed ID: 19189271
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of AFPep, a cyclic peptide with anti-breast cancer properties.
Mansouri W; Fordyce SB; Wu M; Jones D; Cohn D; Lin Q; Feustel P; Sharma T; Bennett JA; Andersen TT
Toxicol Appl Pharmacol; 2018 Apr; 345():10-18. PubMed ID: 29518411
[TBL] [Abstract][Full Text] [Related]
7. Multigenerational reproductive study of genistein (Cas No. 446-72-0) in Sprague-Dawley rats (feed study).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2008 Mar; (539):1-266. PubMed ID: 18685713
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen: 28-day oral toxicity study in the rat based on the Enhanced OECD Test Guideline 407 to detect endocrine effects.
Kennel P; Pallen C; Barale-Thomas E; Espuña G; Bars R
Arch Toxicol; 2003 Sep; 77(9):487-99. PubMed ID: 12802581
[TBL] [Abstract][Full Text] [Related]
9. Effect of tamoxifen on sperm fertilising ability and preimplantation embryo development.
Balasinor N; Parte P; Gill-Sharma MK; Juneja HS
Mol Cell Endocrinol; 2001 Jun; 178(1-2):199-206. PubMed ID: 11403910
[TBL] [Abstract][Full Text] [Related]
10. Maternal exposure to tamoxifen during pregnancy increases carcinogen-induced mammary tumorigenesis among female rat offspring.
Halakivi-Clarke L; Cho E; Onojafe I; Liao DJ; Clarke R
Clin Cancer Res; 2000 Jan; 6(1):305-8. PubMed ID: 10656462
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the 20-day pubertal female assay in Sprague-Dawley rats treated with DES, tamoxifen, testosterone, and flutamide.
Kim HS; Shin JH; Moon HJ; Kim TS; Kang IH; Seok JH; Kim IY; Park KL; Han SY
Toxicol Sci; 2002 May; 67(1):52-62. PubMed ID: 11961216
[TBL] [Abstract][Full Text] [Related]
12. Toxicology and carcinogenesis studies of genistein (Cas No. 446-72-0) in Sprague-Dawley rats (feed study).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2008 Jan; (545):1-240. PubMed ID: 18685716
[TBL] [Abstract][Full Text] [Related]
13. Collaborative work on evaluation of ovarian toxicity. 3) Effects of 2- or 4- week repeated-dose toxicity and fertility studies with tamoxifen in female rats.
Tsujioka S; Ban Y; Wise LD; Tsuchiya T; Sato T; Matsue K; Ikeda T; Sasaki M; Nishikibe M
J Toxicol Sci; 2009; 34 Suppl 1():SP43-51. PubMed ID: 19265288
[TBL] [Abstract][Full Text] [Related]
14. Recovery of reproductive function in rats treated with the aromatase inhibitor fadrozole.
Nunez SB; Blye RP; Thomas PM; Reel JR; Barnes KM; Malley JD; Cutler GB
Reprod Toxicol; 1996; 10(5):373-7. PubMed ID: 8888409
[TBL] [Abstract][Full Text] [Related]
15. Maternal genistein exposure mimics the effects of estrogen on mammary gland development in female mouse offspring.
Hilakivi-Clarke L; Cho E; Clarke R
Oncol Rep; 1998; 5(3):609-16. PubMed ID: 9538161
[TBL] [Abstract][Full Text] [Related]
16. Effects of 2-bromopropane on the female reproductive function in Sprague-Dawley rats.
Lim CH; Maeng SH; Lee JY; Chung YH; Kim TG; Park JH; Moon YH; Yu IJ
Ind Health; 1997 Apr; 35(2):278-84. PubMed ID: 9127562
[TBL] [Abstract][Full Text] [Related]
17. A two-generation oral gavage reproduction study with potassium perfluorobutanesulfonate (K+PFBS) in Sprague Dawley rats.
Lieder PH; York RG; Hakes DC; Chang SC; Butenhoff JL
Toxicology; 2009 May; 259(1-2):33-45. PubMed ID: 19428941
[TBL] [Abstract][Full Text] [Related]
18. Estrous cycle and ovarian changes in a rat mammary carcinogenesis model after irradiation, tamoxifen chemoprevention, and aging.
Karim BO; Landolfi JA; Christian A; Ricart-Arbona R; Qiu W; McAlonis M; Eyabi PO; Khan KA; Dicello JF; Mann JF; Huso DL
Comp Med; 2003 Oct; 53(5):532-8. PubMed ID: 14655997
[TBL] [Abstract][Full Text] [Related]
19. Gestational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) severely alters reproductive function of female hamster offspring.
Wolf CJ; Ostby JS; Gray LE
Toxicol Sci; 1999 Oct; 51(2):259-64. PubMed ID: 10543027
[TBL] [Abstract][Full Text] [Related]
20. Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in female rats.
Terry KK; Cappon GD; Hurtt ME; Tassinari MS; Gupta U
Birth Defects Res B Dev Reprod Toxicol; 2004 Jun; 71(3):150-60. PubMed ID: 15282736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
